Central Pacific Bank Trust Division Sells 339 Shares of Eli Lilly and Company $LLY

Key Points

• Central Pacific Bank Trust Division reduced its stake in Eli Lilly by 4.5%, selling 339 shares and now owning a total of 7,147 shares, valued at approximately $5.57 million.
• Analysts have raised price targets for Eli Lilly, with a consensus rating of "Moderate Buy" and an average target price of $941.35, following strong quarterly earnings performance.
• Eli Lilly recently announced a quarterly dividend of $1.50 per share, representing an annualized yield of 0.8%, with a payout ratio of 39.22%.

Central Pacific Bank Trust Division reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,147 shares of the company's stock after selling 339 shares during the period. Eli Lilly and Company accounts for approximately 0.7% of Central Pacific Bank Trust Division's investment portfolio, making the stock its 22nd biggest position. Central Pacific Bank Trust Division's holdings in Eli Lilly and Company were worth $5,571,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Private Client Services LLC raised its position in Eli Lilly and Company by 7.3% during the 2nd quarter. Private Client Services LLC now owns 1,247 shares of the company's stock worth $972,000 after purchasing an additional 85 shares during the last quarter. AdviceOne Advisory Services LLC raised its position in Eli Lilly and Company by 5.3% during the 1st quarter. AdviceOne Advisory Services LLC now owns 359 shares of the company's stock worth $297,000 after purchasing an additional 18 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs bought a new position in Eli Lilly and Company during the 1st quarter worth $24,539,000. Swedbank AB raised its position in Eli Lilly and Company by 10.3% during the 1st quarter. Swedbank AB now owns 1,255,839 shares of the company's stock worth $1,037,210,000 after purchasing an additional 116,905 shares during the last quarter. Finally, Voya Investment Management LLC raised its position in Eli Lilly and Company by 6.3% during the 1st quarter. Voya Investment Management LLC now owns 1,510,205 shares of the company's stock worth $1,246,687,000 after purchasing an additional 89,167 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price objective for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. Leerink Partners reissued a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $941.35.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $754.90 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $942.35. The firm has a market capitalization of $714.48 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 1.05 and a beta of 0.47. The business has a 50-day simple moving average of $741.03 and a 200 day simple moving average of $777.36. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the company posted $3.92 EPS. The firm's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.